French biotech company Innate Pharma has formed a clinical trial collaboration with AstraZeneca’s research and development arm MedImmune to combine their immunotherapies in the Phase I/II STELLAR-001 clinical trial to treat patients suffering from certain solid tumours.

MedImmune’s durvalumab is an anti-PD-L1 immune checkpoint inhibitor, while Innate’s IPH5401 is an investigational anti-C5aR monoclonal antibody.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Both these cancer immunotherapies leverage immune system of the body to fight against cancer.

Durvalumab is designed to counter the immune-evading capability of a tumour by inhibiting PD-L1 interactions with PD-1 and CD80.

In preclinical studies, C5aR blockade was found to enhance immune-mediated destruction of tumours, as well as the efficacy of checkpoint inhibitors.

“We believe IPH5401 could become an important partner in PD-1/PD-L1 combination strategies.”

Phase I of the new trial is set to determine a recommended dose regimen of IPH5401 when given in conjunction with durvalumab, and Phase II portion will investigate the safety and efficacy of this combination therapy.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Under the non-exclusive agreement between, Innate will perform the trial and costs will be equally shared between the company and MedImmune.

Innate Pharma chief executive officer Mondher Mahjoubi said: “Our collaboration with MedImmune provides further evidence of Innate’s commitment to exploring the full combination potential of IPH5401 as we progress our immuno-oncology portfolio.

“We believe IPH5401 could become an important partner in PD-1/PD-L1 combination strategies.”

The firm is currently under a co-development and commercialisation agreement with AstraZeneca for humanised IgG4, monalizumab, being developed to target NKG2A receptors that are expressed on tumour infiltrating cytotoxic NK and CD8 T lymphocytes.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact